Climb Bio (CLYM) CEO Brennan Aoife awarded 700,000 stock options

Rhea-AI Filing Summary

Climb Bio, Inc. reported an equity award to its President and CEO, Brennan Aoife, who also serves as a director. On January 6, 2026, Aoife received a stock option to buy 700,000 shares of Climb Bio common stock at an exercise price of $3.81 per share. The filing shows this option is held directly and represents 700,000 derivative securities beneficially owned after the grant.

The option was granted as a long-term incentive. According to the vesting terms, 25% of the underlying shares vest on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as Aoife continues to serve the company. The option has an expiration date of January 5, 2036, giving a long window in which it can be exercised if vested.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Aoife

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.81	01/06/2026		A		700,000		(1)	01/05/2036	Common Stock	700,000	$0.00	700,000	D

Explanation of Responses:

1. This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

	/s/ Chandra Adams, as Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Climb Bio (CLYM) disclose in this Form 4?

Climb Bio disclosed that President and CEO, and director, Brennan Aoife received a stock option grant covering 700,000 shares of common stock.

What are the key terms of Brennan Aoife’s stock option grant at Climb Bio (CLYM)?

The option allows Aoife to buy 700,000 shares of Climb Bio common stock at an exercise price of $3.81 per share and expires on January 5, 2036.

How does the 700,000 share stock option for Climb Bio’s CEO vest?

Vesting occurs with 25% of the shares on the first anniversary of the January 6, 2026 grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, subject to continued service.

Is Brennan Aoife’s Climb Bio stock option held directly or indirectly?

The Form 4 indicates the 700,000 stock options are held with direct (D) ownership, with no separate entity listed for indirect ownership.

What role does Brennan Aoife hold at Climb Bio (CLYM) in this filing?

The reporting person, Brennan Aoife, is identified as both a director and an officer, serving as President and CEO of Climb Bio.

Over what period can the newly granted Climb Bio CEO options be exercised?

The stock option granted on January 6, 2026 is scheduled to expire on January 5, 2036, providing a 10-year exercise period, subject to vesting and continued service.